Koneru Hema Manvi, Sarwar Hooria, Bandi Venkata Varshitha, Sinha Mohit, Tarar Pakeeza, Bishara Rafik, Malasevskaia Iana
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Psychiatry, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Cureus. 2024 Sep 18;16(9):e69687. doi: 10.7759/cureus.69687. eCollection 2024 Sep.
Diabetes mellitus represents a significant global health challenge, characterized by impaired insulin production and action, leading to elevated blood glucose levels. This systematic review investigates the association between gut microbiota composition and diversity, along with the structural and functional characteristics of the gut microbiome, and their implications for the risk, prevention, and management of both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a comprehensive search across multiple databases yielded 16 studies that met the inclusion criteria. The findings highlight the potential of gut microbiota interventions, such as fecal microbiota transplantation and probiotic supplementation, in improving metabolic parameters and glycemic control. Notably, the review underscores the importance of dietary interventions and the role of specific microbial populations in influencing diabetes outcomes. Despite the promising results, the variability in study designs, sample sizes, and methodologies poses challenges for generalizability and interpretation. This review emphasizes the need for further research to elucidate the mechanisms underlying these associations and to explore personalized microbiome-based therapies in diabetes management. The insights gained could pave the way for innovative therapeutic strategies aimed at harnessing gut health to mitigate the burden of diabetes mellitus.
糖尿病是一项重大的全球健康挑战,其特征是胰岛素分泌和作用受损,导致血糖水平升高。本系统评价研究了肠道微生物群的组成和多样性、肠道微生物组的结构和功能特征,以及它们对1型糖尿病(T1DM)和2型糖尿病(T2DM)的风险、预防和管理的影响。按照系统评价和Meta分析的首选报告项目(PRISMA)2020指南,在多个数据库中进行全面检索后,得到了16项符合纳入标准的研究。研究结果突出了肠道微生物群干预措施(如粪便微生物群移植和补充益生菌)在改善代谢参数和血糖控制方面的潜力。值得注意的是,该评价强调了饮食干预的重要性以及特定微生物群落在影响糖尿病结局方面的作用。尽管结果很有前景,但研究设计、样本量和方法的差异对结果的普遍性和解释提出了挑战。本评价强调需要进一步研究,以阐明这些关联背后的机制,并探索基于微生物组的个性化糖尿病管理疗法。所获得的见解可能为旨在利用肠道健康减轻糖尿病负担的创新治疗策略铺平道路。